Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wolff

Showing results (681-690 of 831) with videos related to

Pageof 84
Sort By:
JNCI Cancer Spectrum|August 11, 2021
<i>MAF</i> Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical PracticeAlexander H G Paterson, Peter C Lucas, Stewart J Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancerAntonio C Wolff, Ann A Lazar, Igor Bondarenko, et al.
Journal of the National Cancer Institute|April 22, 2016
Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized TrialAmir Sonnenblick, Evandro de Azambuja, Dominique Agbor-Tarh, et al.
Earth'S Future|August 26, 2021
Uncertainty and Bias in Global to Regional Scale Assessments of Current and Future Coastal Flood RiskJ Hinkel, L Feyen, M Hemer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activationLeisha A Emens, Justin M Asquith, James M Leatherman, et al.
Breast Cancer Research and Treatment|October 26, 2019
Breast cancer survivorship care plans: what are they covering and how well do they align with national guidelines?Youngjee Choi, Katherine C Smith, Aishwarya Shukla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2019
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast CancerMothaffar F Rimawi, Polly Niravath, Tao Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2018
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102Noah Kornblum, Fengmin Zhao, Judith Manola, et al.
NPJ Breast Cancer|April 22, 2022
Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuationKaren Lisa Smith, Neha Verma, Amanda L Blackford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2026
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in <i>PALB2</i> or Somatic Mutations in <i>BRCA1</i> or <i>BRCA2</i>Nadine M Tung, Mark E Robson, Tianyu Li, et al.
Pageof 84

Showing results (681-690 of 831) with videos related to

Sort By:
Pageof 84
JNCI Cancer Spectrum|August 11, 2021
<i>MAF</i> Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical PracticeAlexander H G Paterson, Peter C Lucas, Stewart J Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancerAntonio C Wolff, Ann A Lazar, Igor Bondarenko, et al.
Journal of the National Cancer Institute|April 22, 2016
Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized TrialAmir Sonnenblick, Evandro de Azambuja, Dominique Agbor-Tarh, et al.
Earth'S Future|August 26, 2021
Uncertainty and Bias in Global to Regional Scale Assessments of Current and Future Coastal Flood RiskJ Hinkel, L Feyen, M Hemer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activationLeisha A Emens, Justin M Asquith, James M Leatherman, et al.
Breast Cancer Research and Treatment|October 26, 2019
Breast cancer survivorship care plans: what are they covering and how well do they align with national guidelines?Youngjee Choi, Katherine C Smith, Aishwarya Shukla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2019
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast CancerMothaffar F Rimawi, Polly Niravath, Tao Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2018
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102Noah Kornblum, Fengmin Zhao, Judith Manola, et al.
NPJ Breast Cancer|April 22, 2022
Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuationKaren Lisa Smith, Neha Verma, Amanda L Blackford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2026
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in <i>PALB2</i> or Somatic Mutations in <i>BRCA1</i> or <i>BRCA2</i>Nadine M Tung, Mark E Robson, Tianyu Li, et al.
Pageof 84